Abstract
Indevus Pharmaceuticals Inc, under license from Paligent Inc, is developing PRO-2000, an antimicrobial gel for the prevention of HIV infection. The company is also investigating its potential to prevent the transmission of other sexually transmitted diseases. In February 2005, Indevus launched a pivotal phase III trial for the prevention of HIV infection in women. At that time, further phase III trials in 12,000 African women were scheduled to begin in 2005. A second phase III trial began for the prevention of sexually transmitted infections, including HIV, herpes, Chlamydia and gonorrhea, in Africa in October 2005.
MeSH terms
-
Animals
-
Anti-HIV Agents / chemistry
-
Anti-HIV Agents / pharmacology
-
Anti-HIV Agents / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Drug Evaluation, Preclinical
-
Female
-
HIV Infections / prevention & control*
-
HIV-1 / drug effects*
-
Humans
-
Naphthalenesulfonates / chemistry
-
Naphthalenesulfonates / pharmacology
-
Naphthalenesulfonates / therapeutic use*
-
Patents as Topic
-
Polymers / chemistry
-
Polymers / pharmacology
-
Polymers / therapeutic use*
-
Structure-Activity Relationship
-
Vaginal Creams, Foams, and Jellies
Substances
-
Anti-HIV Agents
-
Naphthalenesulfonates
-
PRO 2000
-
Polymers
-
Vaginal Creams, Foams, and Jellies